Section 3 explained: this guide covers what it means, who it applies to, the step-by-step process, documents required, fees, due dates and penalties in India — so you can stay compliant with confidence and avoid costly mistakes.
Paragraphs 10 to 13 of the Biotechnology Patent Guidelines (March 2013) apply four of the section 3 exclusions to living material. The most important for applicants is section 3(c): an organism, sequence, protein or enzyme taken directly from nature is a discovery and cannot be patented, though a process of isolating it can be.
Section 3(b) calls for care with cloning of humans or animals, germ-line modification, harmful animal modification, environmentally risky seeds and commercial use of human embryos (para 10). Section 3(c) excludes micro-organisms, nucleic acid sequences, proteins, enzymes and compounds directly isolated from nature, though isolation processes may be patentable (para 11). Section 3(d) applies to minor modifications and to crystal forms of polypeptides unless improved efficacy is shown (para 12). Section 3(e) excludes compositions of known organisms with no combined effect (para 13). The Guidelines are the Patent Office's guidance and do not have the force of law; the Patents Act, 1970 and the Patents Rules, 2003 as now in force prevail.
The Office revises its guidelines, so check the current version on ipindia.gov.in. This document dates from March 2013. For the same exclusions in the Manual, see our articles on section 3(a), (b), (c), (e) and (f) and section 3(d). A discovery objection on a biotech claim can be met with a patent objection reply that moves the claim from the natural substance to what was made.
Section 3(b): morality, public order and harm (paragraph 10)
Because biotechnology alters the genetic material of organisms, with possible deep effects on the environment and on life, the Guidelines say care is needed in examining the primary or intended use or commercial exploitation of the invention. They list non-limiting examples that may be caught:
- cloning of human beings or animals;
- modifying the germ line of human beings;
- modifying the genetic identity of animals so as to cause them suffering without substantial medical or other benefit, and the resulting animals;
- preparing seeds or other genetic material with elements that might harm the environment;
- using human embryos for commercial exploitation.
An applicant should state the use and benefit plainly and avoid claiming uses that fall into these categories.
Section 3(c): discovery of living things and natural substances (paragraph 11)
The Guidelines say that products such as micro-organisms, nucleic acid sequences, proteins, enzymes and compounds directly isolated from nature are not patentable subject matter, but processes for isolating them can be considered under section 2(1)(j).
| Example in the Guidelines | Outcome | Reason |
|---|---|---|
| A bacterial strain identified by a ribosomal DNA sequence, with a deposit number, isolated from soil | Not patentable | An isolated living substance occurring in nature is a discovery |
| An agent with a stated sequence for promoting cardiac development, obtained from the fluid of horseshoe crab embryos | Not patentable | A peptide that is a non-living substance occurring in nature |
| An isolated peptide that is a structural equivalent of a known protein and inhibits malaria parasites in blood cells | Not patentable | The disclosure does not show what modification was made to the wild-type peptides, and "isolated" means purified from its natural companions, so the functional features are inherent to the natural protein |
The third example is the practical warning. Calling a protein "isolated" or "structurally equivalent" does not change it from the natural material. To move out of section 3(c), the specification must identify what has been altered and how, and the claim must recite it.
Section 3(d): minor changes and crystal forms (paragraph 12)
The Guidelines say minor modifications of an existing substance are not patentable unless improved property or efficacy is established. Two examples:
- A modified pre-protein with a two-amino-acid connecting peptide, where the prior art has a modified protein with a different two-residue peptide. The applicant did not show any therapeutic efficacy over the prior art, so it is not patentable under section 3(d).
- A crystal of a peptide defined by its crystal parameters, where amorphous forms of the peptide are known. No significant improvement in therapeutic efficacy was shown, so it is not allowable.
The Guidelines also state the rule that three-dimensional or crystal structure inventions attract section 3(d) unless the polypeptide differs significantly in properties with regard to therapeutic efficacy. For the pharmaceutical statement of that test, read our article on paragraph 10 of the Pharmaceutical Guidelines; this document dates from 2013 and the Act and Rules as now in force prevail.
Section 3(e): mere admixture (paragraph 13)
The Guidelines state the principle that old integers placed side by side, each doing its own work independently, are not a patentable combination, whereas where they have a working interrelation producing a new or improved result, the interrelation is patentable subject matter. They cite Ram Pratap v Bhabha Atomic Research Centre, as cited in the Guidelines, for the point that a mere juxtaposition of known features arbitrarily chosen from possible combinations is not an invention.
The example is a composition of two naturally occurring fungal species known for controlling plant-parasitic nematodes, combined with enzymes, fats and growth-promoting molecules. Both species are known for the same activity and the specification is silent on any combined effect beyond the sum of their individual effects. The claim is not patentable under section 3(e).
For biotechnology applicants the lesson is the same as in the pharmaceutical field: show comparative data for the combination against each organism alone.
What the examiner checks, and what to file
| Examiner's question | What the applicant should show |
|---|---|
| Is the use or exploitation within the section 3(b) examples? | A stated, lawful use with its benefit |
| Is the claimed organism, sequence, protein or compound as found in nature? | What was modified, how, and the resulting differences from the wild type |
| Is the claim to an isolation process rather than the isolated product? | Process claims with technical steps and a product that is not merely isolated |
| Is a crystal or modified form claimed? | Comparative data on therapeutic efficacy over the known form |
| Is the composition more than the sum of its parts? | Comparative data for the combination and for each component |
How the objection is usually answered
- Section 3(c): amend to a genetically modified organism, a recombinant sequence with stated alterations, or an isolation or production process; point to the passages showing the modification and its effect.
- Section 3(d): supply therapeutic efficacy data against the known form, from the specification.
- Section 3(e): supply synergy data and argue the working interrelation.
- Section 3(b): clarify the intended use and show the claim does not extend to the excluded uses.
A worked example (invented)
Mrida Microbes claims a Bacillus strain isolated from farm soil with a deposit number, as a biofertiliser. The examiner objects under section 3(c). Mrida's specification also describes a strain engineered with an added gene that increases phosphate solubilisation, and a method of producing a stable formulation. Mrida amends to the engineered strain, states the gene and its effect in the claim, and adds a method claim for the formulation. It drops the natural isolate. The claim now covers what was made, not what was found.
Common lapses
- Claiming a natural strain or sequence with a deposit number as if the deposit made it an invention.
- Using "isolated" or "purified" as the only feature of a peptide or enzyme claim.
- Claiming a crystal form without efficacy data.
- Combining two known organisms with no combination data.
Need help with a section 3 objection on a biotech claim?
The usual task is to move the claim from the natural material to the modification or process the specification supports. Our team can review the specification and prepare the reply. See patent objection reply, and read next on methods of agriculture, treatment, plants and animals under section 3(h), (i) and (j).
Key takeaways
- Organisms, sequences, proteins and compounds taken directly from nature are discoveries under section 3(c).
- Isolation processes may be patentable if they meet section 2(1)(j).
- "Isolated" does not turn a natural peptide into an invention.
- Crystal forms and minor modifications need efficacy data under section 3(d).
- Mixtures of known organisms need a combined effect to pass section 3(e).
Read next
- Biotechnology Patent Guidelines 2013, paragraphs 6 to 9: novelty, sequence claims, inventive step
- Biotechnology Patent Guidelines 2013, paragraphs 14 to 18: section 3(h), (i), (j), (k) and (p)
- Manual Chapter 9: section 3(d)
- Patent for Biotech Inventions: Micro-organisms and Genes
Disclaimer: Based on the manuals and guidelines published by the Office of the Controller General of Patents, Designs and Trade Marks that are named in the article, as consulted on 4 October 2026. They are guidance and do not have the force of law; the Patents Act, 1970 and the Patents Rules, 2003 as amended (including the 2024 amendment rules) prevail, and the current versions on ipindia.gov.in should be checked. This article is general information, not legal advice; check the official text before acting.